# DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry

> **NCT03985501** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 1431 (actual)

## Conditions studied

- Sickle Cell Disease
- Infant, Newborn, Disease
- Drepanocytosis

## Interventions

- **OTHER:** SCD newborn screening with the MS/MS method from Zentech

## Key facts

- **NCT ID:** NCT03985501
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2022-12-10
- **Final completion:** 2022-12-10
- **Target enrollment:** 1431 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03985501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03985501, "DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03985501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*